title: [Determination of anti-Xa activity in cancer patients].
abstract: Low molecular-weight heparins (clexan, fraxiparin, fragmin) were used in cancer patients to prevent hemostatic system disorders and related complications. The adequacy and safety of therapy were assessed measuring plasma anti-Xa activity in 239 patients. When the prophylactic doses of the low molecular-weight heparins clexan, fraxiparin, and fragmin were given, their anticoagulative effect was similar as judged from anti-Xa activity. Clexan exhibited the maximum anti-Xa activity when the therapeutic doses of the low molecular-weight heparins were used.
authors.forename: O V
authors.initials: OV
authors.lastname: Somonova
authors.forename: A V
authors.initials: AV
authors.lastname: Madzhuga
authors.forename: A L
authors.initials: AL
authors.lastname: Elizarova
authors.forename: G N
authors.initials: GN
authors.lastname: Zubrikhina
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D017985:Dalteparin / Q000009:adverse effects / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use; D065427:Factor Xa Inhibitors; D006801:Humans; D017762:Nadroparin / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000097:blood* / Q000150:complications / Q000628:therapy; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D017762:Nadroparin; D017985:Dalteparin